Aytu BioPharma Posts $0.20 Per-Share Loss as Revenue Grows 6.9%
Key Facts
Aytu BioPharma said on November 16, 2026, that it posted a net loss of $3.9 million, or $0.20 per basic and diluted share, in the first quarter of fiscal 2027 ended September 30. The company compared that with net income of $2.0 million in the year-earlier period, with basic earnings of $0.21 per share and a diluted loss of $0.08 per share. Net revenue was $14.8 million, up 6.9% from $13.9 million a year earlier. Sales growth came amid mixed product performance, as revenue from EXXUA and the pediatric portfolio rose while sales from the ADHD drug portfolio fell. The company announced the results alongside a definitive agreement for Rosemont to acquire it for cash, putting operating performance and the deal at the center of its disclosure.
EXXUA generated net revenue of $4.9 million, compared with $3.9 million in the fourth quarter of fiscal 2026, an increase of 24.5% sequentially. Prescriptions rose 32.5% sequentially during the quarter to 4,400. Chief Executive Josh Disbrow said quarterly performance was led by the drug's growth, noting that prescriptions increased about 33% from the June quarter. Monthly prescriptions peaked at about 1,650 in September 2026. The company had no EXXUA revenue in the year-earlier quarter, while current-period revenue reflects sales to distribution channels and estimates of gross discounts and deductions.
By contrast, revenue from the ADHD portfolio fell to $7.7 million from $13.2 million in the first quarter of fiscal 2026. The company attributed the decline primarily to reduced promotion as it shifted commercial resources toward EXXUA, along with competition from generic drugs. Teva launched a generic version of one ADHD product in late fiscal 2026's second quarter, according to the company's disclosure. Revenue from the pediatric portfolio rose to $2.2 million from $0.7 million in the year-earlier period. The company linked the increase mainly to an improved payer mix and lower returns.
Gross profit rose to $9.4 million from $9.2 million, but gross margin fell to 63.6% from 66.1%. The company cited higher royalty expenses, primarily related to EXXUA. Operating expenses increased to $13.4 million from $10.7 million a year earlier. It attributed the increase to labor and travel costs supporting EXXUA marketing, higher legal expenses that included merger costs, and a cancellation fee paid to a contract manufacturer. Adjusted earnings before interest, taxes, depreciation and amortization showed a loss of $2.6 million, compared with a loss of $0.6 million, which the company said primarily reflected continued investment in EXXUA marketing.
The company said both periods included a noncash gain on derivative warrant liabilities, amounting to $0.3 million in the current quarter and $3.8 million in the year-earlier quarter. In the prior period, the company recorded net income of $2.0 million and basic earnings of $0.21 per share, while the diluted loss was $0.08 per share. This comes amid differing effects of noncash gains on earnings figures between the two periods. Net cash used in operating activities was $0.3 million, compared with $0.6 million a year earlier. The company also used $0.5 million in financing activities, mainly to repay debt.
Under the definitive agreement announced on November 16, Rosemont will acquire Aytu through a cash tender offer of $2.70 per share, followed by a merger. The company estimated total consideration at about $56 million on a fully diluted basis. Disbrow said the agreement reflected the company's building of its central nervous system and pediatric portfolios, and described it as a strategic fit. The company expects to complete the deal by the end of calendar 2026, subject to customary closing conditions, including tender by holders of a majority of the outstanding shares. The tender offer had not begun when the statement was issued, and the company said it would not hold a conference call to discuss the results because of the pending merger. AYTU shares closed at $1.78 on November 13, 2026, the latest closing price included in the data available in the report.